Get started
BIOMARIN PHARMACEUTICALBIOMARIN PHARMACEUTICALBIOMARIN PHARMACEUTICAL

BIOMARIN PHARMACEUTICAL

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

1BMRN chart


Full chart

1BMRN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.20 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
36.90
Basic EPS (TTM)
1.52 EUR
Net income (FY)
‪151.89 M‬ EUR
Revenue (FY)
‪2.19 B‬ EUR
Shares float
‪188.20 M‬
Beta (1Y)
0.38

Employees


Employees (FY)
‪3.4 K‬
Change (1Y)
+319 +10.35%
Revenue / Employee (1Y)
‪711.38 K‬ EUR
Net income / Employee (1Y)
‪49.29 K‬ EUR

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG01K3X4DP8
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

1BMRN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

1BMRN highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
4.87%
Maturity date
May 15, 2027

Explore more bonds 

Sparks


Curated watchlists where 1BMRN is featured.

See all sparks 

Frequently Asked Questions


The current price of 1BMRN is 59.54 EUR — it has increased by 0.88% in the past 24 hours. Watch BIOMARIN PHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BIOMARIN PHARMACEUTICAL stocks are traded under the ticker 1BMRN.
1BMRN stock has fallen by −5.13% compared to the previous week, the month change is a −8.51% fall, over the last year BIOMARIN PHARMACEUTICAL has showed a −23.84% decrease.
We've gathered analysts' opinions on BIOMARIN PHARMACEUTICAL future price: according to them, 1BMRN price has a max estimate of 119.84 EUR and a min estimate of 61.33 EUR. Watch 1BMRN chart and read a more detailed BIOMARIN PHARMACEUTICAL stock forecast: see what analysts think of BIOMARIN PHARMACEUTICAL and suggest that you do with its stocks.
1BMRN reached its all-time high on Jan 3, 2024 with the price of 91.38 EUR, and its all-time low was 60.30 EUR and was reached on Nov 5, 2024. View more price dynamics on 1BMRN chart.
See other stocks reaching their highest and lowest prices.
1BMRN stock is 0.87% volatile and has beta coefficient of 0.38. Track BIOMARIN PHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMACEUTICAL there?
Today BIOMARIN PHARMACEUTICAL has the market capitalization of ‪11.31 B‬, it has decreased by −4.76% over the last week.
Yes, you can track BIOMARIN PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMACEUTICAL is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
1BMRN earnings for the last quarter are 0.49 EUR per share, whereas the estimation was 0.48 EUR resulting in a 3.59% surprise. The estimated earnings for the next quarter are 0.52 EUR per share. See more details about BIOMARIN PHARMACEUTICAL earnings.
BIOMARIN PHARMACEUTICAL revenue for the last quarter amounts to ‪669.78 M‬ EUR, despite the estimated figure of ‪631.78 M‬ EUR. In the next quarter, revenue is expected to reach ‪676.75 M‬ EUR.
1BMRN net income for the last quarter is ‪95.27 M‬ EUR, while the quarter before that showed ‪100.06 M‬ EUR of net income which accounts for −4.78% change. Track more BIOMARIN PHARMACEUTICAL financial stats to get the full picture.
No, 1BMRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has ‪3.40 K‬ employees. See our rating of the largest employees — is BIOMARIN PHARMACEUTICAL on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMACEUTICAL EBITDA is ‪440.48 M‬ EUR, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHARMACEUTICAL financial statements.
Like other stocks, 1BMRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMACEUTICAL technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMACEUTICAL stock shows the sell signal. See more of BIOMARIN PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.